论文部分内容阅读
目的：观察成人急性白血病（ＡＬ） 患者完全缓解（ＣＲ） 后强化治疗的效果。方法：对６７ 例ＣＲ后的成人ＡＬ患者进行强化治疗，急性髓细胞性白血病（ＡＭＬ）以中剂量阿糖胞苷（ＩＤ－ Ａｒａ－ Ｃ）方案为主，急性淋巴细胞性白血病（ＡＬＬ）以中剂量氨甲蝶呤（ＩＤ－ ＭＴＸ）方案为主。结果：４８ 例ＡＭＬ患者中位ＣＲ 期１６ 个月，预期３ 年和４ 年无病生存（ＤＦＳ）为３６９％ 和２１１ ％ ；２３ 例（４７９ ％） 患者复发。１９ 例ＡＬＬ 患者中位ＣＲ 期１４ 个月，预期４ 年ＤＦＳ 为３１５％ ；１０ 例（５２６％ ） 患者复发。结论：以ＩＤ－ Ａｒａ－ Ｃ 为主的强化方案及以ＩＤ－ ＭＴＸ 为主的强化方案分别能延长ＡＭＬ及ＡＬＬ患者的ＤＦＳ，降低复发率
Objective: To observe the effect of intensive treatment after complete remission (CR) in adult acute leukemia (AL) patients. METHODS: Intensive treatment was performed on 67 adult patients with AL after CR. Acute myeloid leukemia (AML) was mainly treated with ID-Ara-C and acute lymphoblastic leukemia (ALL). The medium-dose methotrexate (ID-MTX) regimen is predominant. RESULTS: The median CR of 16 patients with AML was 16 months, and the expected disease-free survival (DFS) at 3 years and 4 years was 36.9% and 21.1%, respectively; 23 patients (47.9%) had recurrence. 19 patients with ALL had a median CR of 14 months, and 4 years had a DFS of 31.5%; 10 patients (52.6%) had relapses. Conclusion: ID-Ara-C-based enhancement regimen and ID-MTX-based enhancement regimen can prolong DFS in patients with AML and ALL, respectively, and reduce the recurrence rate.